Cytomx Therapeutics vs Pyxis Oncology
Cytomx Therapeutics is the larger business, with $76.2m of revenue in fiscal 2025 against $13.9m for Pyxis Oncology (5.5 times as much). Pyxis Oncology grew faster (-14.2% against -44.8%). Cytomx Therapeutics kept more of each dollar of sales as profit: a net margin of -22.8% against -574.5%. Cytomx Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Cytomx TherapeuticsCTMX, 2025 | Pyxis OncologyPYXS, 2025 |
|---|---|---|
| Revenue | $76.2m | $13.9m |
| Revenue growth | -44.8% | -14.2% |
| Net income | −$17.4m | −$79.6m |
| Operating margin | -29.3% | -609.2% |
| Net margin | -22.8% | -574.5% |
| Return on equity | -35.2% | -91.4% |
| Free cash flow | −$75.8m | −$63.5m |
| Cash | $12.7m | $15.4m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 69 | 56 |
| Market value | $372m | $104m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 0 buys, 7 sales | 1 buys, 1 sales |